Gedeon Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe’s largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women’s Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation.
Among Gedeon Richter‘s assets is a manufacturing plant in Russia, opened in 2001 — the company’s first foreign production facility.
According to the annual “Farmacevticheskiy Vestnik” ranking of industry influence, Gedeon Richter has consistently ranked among the top 10 most influential foreign pharmaceutical manufacturers in Russia for several years in a row. IQVIA’s 2024 report places Gedeon Richter among the top 10 pharmaceutical retail market companies by revenue in rubles.